This study examines the role of real-world evidence (RWE) in European health technology assessment (HTA), focusing on its acceptance, use, and best practices across different HTA bodies. It analyzes the variability in RWE acceptance among HTA agencies and provides insights into the factors influencing its use in decision-making.
